Physician profile
David R Close
NPI 1326002130
$2,149.52
in general payments reported to CMS, 2019-2025
28 companies · $785 in 2025
The $785 reported for 2025 was less than what a typical Medical Oncology provider received nationally (typical 2025 total: $1,158).
Payments by year
General payments by program year, as reported to CMS.
General payments by year: 2019: $870 · 2020: $157 · 2021: $100 · 2022: $41.10 · 2023: $102 · 2024: $94.49 · 2025: $785.
What the payments were for
Nature of payment as categorized by the reporting companies: meals, consulting, travel, and so on.
Food and Beverage: $919 · Education: $62.58.
View as a table
| Payment type | Amount (2023-2025) |
|---|---|
| Food and Beverage | $918.60 |
| Education | $62.58 |
Payment-type detail covers 2023-2025; earlier years are included in totals but not broken out here.
Who reported paying
General payments only, as reported to CMS. Product names cover 2023-2025.
| Company | General payments | Years | Top products |
|---|---|---|---|
| Pfizer INC. | $346.30 | 2019-2025 | |
| Novartis Pharmaceuticals Corporation | $280.11 | 2019-2025 | |
| Astrazeneca Pharmaceuticals Lp | $226.89 | 2019-2025 | Calquence, Imfinzi, Lynparza |
| Janssen Biotech, INC. | $121.11 | 2019-2025 | Erleada, Talvey, Carvykti |
| Jazz Pharmaceuticals INC. | $113.16 | 2019-2025 | |
| Seagen INC. | $106.24 | 2019-2021 | |
| E.R. Squibb & Sons, L.L.C. | $85.32 | 2019-2025 | Opdivo |
| Abbvie INC. | $82.64 | 2024-2025 | |
| Merck Sharp & Dohme LLC | $82.63 | 2019-2025 | Keytruda, Lynparza |
| Amgen INC. | $78.88 | 2019-2020 | |
| Genentech USA, INC. | $78.46 | 2019-2025 | Polivy, Tecentriq, Tecentriq Hybreza |
| Incyte Corporation | $68.75 | 2019-2025 | Jakafi, Monjuvi, Pemazyre |
| Celgene Corporation | $55.92 | 2019-2025 | Reblozyl |
| Array Biopharma INC | $55.58 | 2025 | Mektovi, Braftovi, Lorbrena |
| Gilead Sciences, INC. | $48.12 | 2019-2021 |
Show all 28 companies
| Company | General payments | Years | Top products |
|---|---|---|---|
| Ipsen Biopharmaceuticals, INC | $42.10 | 2019-2025 | Onivyde |
| Genmab U.S., INC. | $39.02 | 2023 | Epkinly |
| Daiichi Sankyo INC. | $38.46 | 2020-2022 | |
| Rigel Pharmaceuticals, INC. | $37.29 | 2019-2020 | |
| Emd Serono, INC. | $34.98 | 2019-2020 | |
| Eisai INC. | $27.01 | 2019-2020 | |
| Teva Pharmaceuticals USA, INC. | $17.35 | 2019 | |
| Regeneron Healthcare Solutions, INC. | $16.31 | 2019 | |
| Astellas Pharma US INC | $16.11 | 2019 | |
| Lilly USA, LLC | $15.88 | 2019 | |
| Pharmacyclics LLC, An Abbvie Company | $13.05 | 2019 | |
| Genzyme Corporation | $11.67 | 2019 | |
| Clovis Oncology, INC. | $10.18 | 2019 |
Drugs and devices associated with these payments
CMS records which products a payment was associated with, not how the money was allocated. Association is not allocation: one payment can be associated with several products, and a product listing does not mean the payment was made because of that product. Product detail covers 2023-2025.
If you want to bring it up
Most clinicians are glad to talk about this. A respectful way in:
- "I saw David Close listed in the CMS Open Payments database. Can you tell me about your work with those companies?"
- "Is there a generic or alternative to this medication, and would it work as well for me?"
- "What made you choose this particular treatment for my situation?"
These are normal questions. A good clinician will welcome them.
Share this page
Keep an eye on this page
Get an email when the next June refresh changes this page. No account needed.
Source: CMS Open Payments, program years 2019-2025, as reported to CMS by drug and device makers (published June 30, 2026). Drug and device detail covers 2023-2025.